Lisata Therapeutics Inc Stock Price, News & Analysis

Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, will release its Q2 2025 financial results on Thursday, August 7, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register to receive dial-in details and are encouraged to join 15 minutes before the start time. A live webcast will be available on Lisata's website, with a 12-month replay option.

Lisata Therapeutics (Nasdaq: LSTA) announced the completion of patient enrollment in their Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC).

The trial's preliminary data, presented at ESMO-GI 2025, showed remarkable results: an overall response rate of 60% and a disease control rate of 100%. Of the 20 participants, 13 showed partial response, 1 exhibited complete response, and 6 demonstrated stable disease. Additionally, 16 out of 20 participants experienced decreased CA19-9 levels, with 7 showing >90% reduction.

The study, conducted at St John of God Subiaco Hospital in Australia, divided participants into three cohorts, with the largest group (Cohort 3, n=20) receiving the full combination therapy of chemotherapy, durvalumab, and certepetide.

Lisata Therapeutics (Nasdaq: LSTA) has secured a new composition of matter patent for certepetide from the USPTO, extending protection until March 2040 with potential for further extension. The patent (U.S. Patent No. 12,351,653) covers certepetide's chemical structure, pharmacokinetic properties, manufacturing methods, and applications for treating solid tumor cancers.

This strategic development provides Lisata with the strongest form of IP protection, preventing others from manufacturing or selling the drug. CEO David J. Mazzo emphasized that this patent milestone enhances certepetide's commercial value by delaying generic competition and strengthens the company's position in potential partnership negotiations.

Lisata Therapeutics (NASDAQ:LSTA) announced positive preliminary results from Cohort B of the ASCEND Phase 2b trial evaluating certepetide in metastatic pancreatic cancer. The trial, conducted across 24 sites in Australia and New Zealand, demonstrated significant improvements in patient outcomes.

Key findings include progression-free survival of 60.8% vs 25% (certepetide vs placebo), median progression-free survival of 7.5 vs 4.7 months, and objective response rate of 45.2% vs 19%. Median overall survival improved to 10.32 months vs 9.23 months. The Cohort B regimen, which added a second dose of certepetide, showed meaningful improvements compared to Cohort A's single-dose approach.

Final data from both cohorts is expected later this year, with results suggesting certepetide could potentially transform treatment for metastatic pancreatic cancer, which currently has a five-year survival rate of just 13%.

Lisata Therapeutics (NASDAQ: LSTA) and GATC Health Corp. have expanded their strategic alliance to enhance drug discovery and development using AI technology. The partnership combines Lisata's drug development expertise with GATC's Multiomics Advanced Technology (MAT) platform. A key focus is advancing GATC's AI-discovered therapeutic for opioid use disorder (OUD) into Phase 1 human trials in early 2026. The MAT platform, validated by UC Irvine with 86% sensitivity and 91% specificity, will help identify new combination therapies and predict safety and efficacy. GATC will cover R&D costs while Lisata receives milestone fees and royalties from commercialized products. The collaboration aims to accelerate drug development, potentially reducing discovery time from 5-6 years to one year and creating up to $400 billion in value for the pharmaceutical industry by end-2025.

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and serious diseases, announced its participation in the 2025 BIO International Convention. CEO David J. Mazzo will deliver a corporate overview presentation on Tuesday, June 17th at 11:15 a.m. Eastern Time in Room 153A. The convention will be held in Boston, MA from June 16-19, 2025. Interested parties can register for the conference and schedule one-on-one meetings with Lisata's management team through the BIO convention's registration website.

Lisata Therapeutics (NASDAQ: LSTA) reported Q1 2025 financial results and provided updates on its clinical development portfolio. The company's lead drug certepetide showed encouraging results in multiple trials, including positive trends in the ASCEND trial's Cohort A for pancreatic cancer treatment. Key financial metrics show net losses of $4.7 million for Q1 2025, down from $5.4 million in Q1 2024, with cash reserves of $25.8 million expected to fund operations into Q3 2026. Operating expenses decreased 11.4% to $5.8 million. The company is advancing multiple clinical trials, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, across various solid tumor types. Notably, Cohort B results from the ASCEND trial have been accepted for oral presentation at ESMO-GI 2025, and the company maintains strategic partnerships with Qilu Pharmaceutical, Catalent, and other organizations.

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, has scheduled its Q1 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.

Participants must pre-register for the conference call through a provided link. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.

Lisata Therapeutics (NASDAQ: LSTA) has entered into a research license agreement with Catalent to evaluate the combination of Lisata's certepetide with Catalent's SMARTag® antibody-drug conjugate (ADC) platform for treating advanced solid tumors.

Under the agreement, Catalent will fund all research and development while Lisata provides consulting support. Lisata will receive an upfront payment and potential future considerations based on preclinical evaluation results.

The collaboration aims to enhance ADC therapy by combining certepetide's tumor penetration capabilities with ADC's targeted delivery of cytotoxic drugs. This combination could potentially improve treatment efficacy while reducing systemic toxicity. Additionally, certepetide is expected to reduce the immunosuppressive nature of the tumor microenvironment (TME), potentially improving patient response to ADC therapy.